There are currently 1621 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and University of Maryland. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/27/2024
Locations: Xentria Investigative Site, Baltimore, Maryland
Conditions: Pulmonary Sarcoidosis
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Recruiting
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Small Cell Lung Carcinoma
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Recruiting
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: GIST
Early Detection of Pancreatic Cystic Neoplasms
Recruiting
This research is being done to learn more about pancreatic cysts. The tests that are currently available are imperfect at determining exactly what type of pancreatic cyst a person has, which cysts contain cancer, or what the risk is of developing cancer in the future. The aim of this study is to use a combination of clinical, imaging, cyst fluid analysis, and molecular markers to try to help develop better tools to answer these questions.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pancreatic Cysts, Intraductal Papillary Mucinous Neoplasm, Pancreatic Mucinous-Cystic Neoplasm, Cystic, Mucinous and/or Serous Neoplasm, Solid Pseudopapillary Tumour of the Pancreas
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Recruiting
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/27/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland +2 locations
Conditions: Atherosclerotic Cardiovascular Disease
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Gender:
Male
Ages:
50 years and above
Trial Updated:
03/27/2024
Locations: Chesapeake Urology, Baltimore, Maryland +1 locations
Conditions: Prostate Cancer
AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or loca... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/27/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Advanced MTAP-null Solid Tumors
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Recruiting
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Gender:
All
Ages:
111 days and below
Trial Updated:
03/27/2024
Locations: Johns Hopkins Children's Center, Baltimore, Maryland
Conditions: Biliary Atresia
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Recruiting
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/27/2024
Locations: John Hopkins Hospital, Baltimore, Maryland
Conditions: Kidney Transplantation in Highly Sensitized Patients
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
All
Ages:
Between 12 years and 28 years
Trial Updated:
03/27/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Type 1 Diabetes Mellitus
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Recruiting
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the stud... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Primary Sclerosing Cholangitis